About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Journal of Interferon
& Cytokine Research

Editors-in-Chief: Ganes C. Sen and Thomas A. Hamilton

ISSN: 1079-9907 • Published Monthly • Online ISSN: 1557-7465

Current Volume: 34

Latest Impact Factor* is 3.899

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Statement of Purpose and Policy

    Journal of Interferon & Cytokine Research publishes original articles in the following formats; research reports, short communications, review articles and correspondence, covering all aspects of interferon and cytokine research ranging from the molecular biology of interferon and cytokine systems to their use in the clinic.

    Manuscript Submissions

    Please submit manuscripts online using the following URL:  http://mc.manuscriptcentral.com/interferoncytokine

    Create An Account in Manuscript Central

    If you do not already have an account in Manuscript Central for Journal of Interferon and Cytokine Research, you will need to create one. Once you create your account, you may log in to the system to begin your submission.

    Use of English Language

    All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Journal of Interferon and Cytokine Research. For authors whose native language is not English, we suggest using a service that can aid in the translation and rewriting of material into correct and proper English usage. The Publisher offers this service with a subsidy from the author prior to official submission. It is important to note that employing the use of the Publisher's service does not guarantee acceptance of any paper. All submissions are subject to peer review.


    It is incumbent upon the submitting author to ensure the accuracy and inclusion of all contributing authors' names and affiliations upon original submission of the paper. Once a paper is accepted for publication, changes in authorship – including the page proof stage – are NOT permitted. Changes in authorship after publication are strictly prohibited.

    Corresponding Author

    It is the Journal's policy that a manuscript has only ONE corresponding author listed on a paper. This designation should be determined at the time of submission. Additions to corresponding authors are not permitted after acceptance or in page proofs.

    Peer Review

    All submissions to the Journal are subject to peer review. Authors are encouraged, but not required, to supply the names and email addresses of up to five potential reviewers, as well as the names of individuals whom the authors would prefer not be selected as a reviewer. However, the review selection is ultimately at the discretion of the Editor.

    Expedited Peer-Review

    An option for an expedited peer-review process is available in which a final decision including the referees' critiques will be forwarded to the corresponding author within a three-week period from the receipt of the completed manuscript at the editorial office. The cost for this service is $250.00 and is paid by the corresponding author. A payment window will appear when all files have been downloaded. We accept American Express/Optima, VISA, and MasterCard.

    Color Illustrations

    Color figures submitted for peer-review are expected to be published in color. Authors should determine that the use of color is essential prior to submission, and the cost for color printing must be subsidized by the author(s). Price estimates are available from the Publisher upon request. Please consider these expenditures when preparing your manuscript for submission.

    Page Charges

    To help defray the cost of printing, the Publisher requests that page charges, currently $65 per printed page, be paid by all authors who have funds available from research grants or from their institutions. These payments are not a prerequisite for the publication of any article.

    Editorial Policy

    The Journal of Interferon and Cytokine Research publishes manuscripts that are original works, no part of which have been submitted for publication or published elsewhere except as brief abstracts. Duplicate publication, falsification, plagiarism (including self-plagiarism), or fabrication will be considered actionable misconduct. All submitted manuscripts will be processed through plagiarism detection software. Misconduct does not include honest error or differences in interpretations or judgments of data. All authors are deemed to be individually and collectively responsible for the content of papers and must acknowledge their approval of the submitted manuscript. Citations for personal communication and other contributions not recognized by authorship are also subject to this expectation.

    The Editors-in-Chief are responsible for the editorial conduct of the Journal and for compliance with relevant policies and procedures. When an allegation of misconduct is raised regarding a manuscript the Editors will take the following course of action. Review and processing of unpublished manuscripts will stop while no immediate action will be taken for published work until the matter is resolved. The Editors will provide details of the allegation to the corresponding author(s) and/or specifically identified author(s) in a nonjudgmental manner and request some explanatory response. While the Editors are obligated to ensure that the suspicion of misconduct has been addressed, they do not make such determinations. Should the author's response fail to resolve the situation satisfactorily, the Editors reserve the right to forward relevant material to the appropriate authorities at the author's institution for further investigation. Until the matter is clarified, no papers by involved authors of the disputed manuscript will be considered for publication. Issues relating to contested authorship will be handled by the same procedure.

    If scientific misconduct is confirmed by institutional review, the Editor-in-Chief will decide upon the appropriate action which may include official withdrawal of a published article, rejection of a manuscript at any stage before publication, or letter of reprimand. If no scientific misconduct is found, the manuscript (if unpublished) will be scheduled for publication. For errors in a published article not deemed to be misconduct, an Erratum or Letter to the Editor will be published.


    Upon acceptance of any manuscript processed through Manuscript Central, all authors will receive a follow-up email with instructions on completing our online Copyright Agreement form. Each author will receive individualized links to their copyright form. Authors will not be permitted to “share” or forward these individualized links as they are unique to each author. Therefore, it is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to ensure the proper delivery of each copyright form, and any other pertinent email communications.

    The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.

    Failure by all authors to submit this form will result in a delay in publication.


    The author must obtain permission whenever it is required in conjunction with the reproduction of material such as figures and tables from copyrighted material. Written permission must be obtained from the publisher (not the author or editor) of the journal or book concerned. The publication from which the figure or table is taken must be included in the reference list. All permission listings must be shown in the manuscript—they cannot be entered on proofs. Written permission must be obtained from the author of any unpublished material cited from other laboratories, and should accompany the manuscript.

    Patient Release Information

    If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients. The submitting author should provide written confirmation of this critical information. Acceptable forms of consent statements are emails or letters. The Journal does not provide a generic patient release form.

    The written consent must contain specific information about the patient's name, age, and if pertinent, conservatorship – as well as stated permission – granting the Journal the rights to publish the photograph within its pages (which includes the name of the Journal and article title).


    Research Reports should follow the format provided in detail below.

    Short Communications should present observations that are complete but do not require a full-length text. Format similar to Research Reports should be used with the following exceptions: section headings should not be used in the body of a short communication. Both the text and the number of figures should be kept to a minimum. Total length of your paper should not exceed 4,000 words, excluding abstract, references, figures and tables. Maximum of 60 references and 5 display items (e.g. figures, tables).

    Review Articles should cover areas of topical interest in the basic biology or interferons and cytokines or their use in the clinic. The recommended length is 4–8 journal pages (approximately 1000 words/page) with 2–3 diagrams or illustrations. Reference citations require full titles and complete pagination.

    Correspondence In addition to the above formats, the Journal will consider the publication of various forms of correspondence relating to the research community involved in interferon and cytokine research including letters to the editor, meeting reports, historical perspectives etc. Please contact the Editors-in-Chief if you would like to submit a correspondence.

    Preparation of Research Reports

    Title Page

    Please note that information entered in the online submission form will be used for publication purposes (e.g., author contact information and affiliations). Please also include the following information on the title page:

    Title: Titles should be no more than three typeset lines (generally 135 characters including spaces) and should be comprehensible to a broad scientific audience. Please provide a running title of fewer than 40 characters.

    Author affiliation: Include department, institution, and complete address, with the ZIP/postal code, for each author. Use superscripts to match authors with institutions.

    Corresponding author: The name, complete address, telephone number, and e-mail address of the author to whom correspondence and proofs should be sent.

    Keywords: At least three keywords are required during the manuscript submission process.


    Supply an abstract of no more than 200 words stating the aims, results, and conclusions drawn from the study. Do not include section headings. Reference citations are not permitted in the abstract.


    The Introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible but can include a short historical review where desirable.

    Materials and Methods

    This section should contain sufficient detail, so that all experimental procedures can be reproduced, and include references. Methods, however, that have been published in detail elsewhere should not be described in detail. Authors should provide the name of the manufacturer and their location for any specifically named medical equipment and instruments, and all drugs should be identified by their pharmaceutical names, and by their trade name if relevant.


    The Results section should briefly present the experimental data in text, tables or figures. Tables and figures should not be described extensively in the text, either.


    The discussion should focus on the interpretation and the significance of the findings with concise objective comments that describe their relation to other work in the area. It should not repeat information in the results. The final paragraph should highlight the main conclusion(s), and provide some indication of the direction future research should take.


    These should be brief, and should include sources of support including sponsorship (e.g. university, charity, commercial organization) and sources of material (e.g. novel drugs) not available commercially.

    Disclosure Statement

    Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the article, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the article is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at www.icmje.org for further guidance. If no conflicts exist, the authors must state ‘‘No competing financial interests exist.’’


    A complete list of authors, titles, and page numbers must be included in each reference. Each reference must be cited in the text and listed in parentheses with author last name and year of publication (see examples below; three or more authors should be listed as (Author and others 2005). Reference list must be typed double spaced and references listed alphabetically. When data from an unpublished source are given, supply complete information, e.g., the researcher's name and location. If work is in press, give the journal in which it is to be published.

    This reference style (J Interferon Cytokine Res) can be accessed in EndNote. Visit www.EndNote.com and search for the Journal title to download the output style.

    Journal Article:

    Single Author

    Trinchieri G. 1989. Biology of natural killer cells. Adv Immunol 47:187–201.

    In-text: (Trinchiere 1989)

    Multiple Authors

    Meise CJ, Johnson DL, Stehlik LL, Manderson J, Shaheen P. 2003. Growth rates of juvenile winter flounder under varying environmental conditions. TransAmFish Soc 132(2):225– 345.

    In-text: (Meise et al 2003)


    McCormac JS, Kennedy G. 2004. Birds of Ohio. Auburn (WA): Lone Pine. 360?p.

    In-text: (McCormac and Kennedy 2004)

    Book Chapter:

    McDaniel TK, Valdivia RH. 2005. New tools for virulence gene discovery. In: Cossart P, Boquet P, Normark S, Rappuoli R, editors. Cellular microbiology. 2nd ed. Washington (DC): ASM Press. p 473–488.

    In-text: (McDaniel and Valdivia 2005)

    Tables and Illustrations. Use Arabic numerals to number tables. Remember, each table must stand alone, i.e., contain all necessary information in the caption, and the table itself must be understood independently of the text. Information that appears in the text should not be repeated in tables, and tables should not contain data that can be given in the text in one or two sentences.

    Below are the guidelines for the submission of artwork:

    • Line illustrations should be submitted at 1200 ?DPI.

    • Halftones and color should be submitted at a minimum of 300 ?DPI.

    • Save and upload art as either TIFF or EPS files. Avoid submitting JPEG files.

    • Color art must be saved as CYMK - not RGB.

    • PowerPoint, Excel, and PDF files are NOT acceptable.

    • When naming your figure files, please label them with the submitting author's last name, followed by the figure number (Ex: SmithFig2). Name figure files using only alphanumeric characters. Do not use symbols, dots, or dashes.

    IMPORTANT: Please upload individual files of all manuscript material—do NOT upload a single PDF file containing all text, figure, and table files of your article. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.

    Style Guide

    • Text should be saved as a MS Word file

    • Text should be double spaced

    • All pages and lines are to be numbered

    • Include the first author's name on each page

    • Abbreviations should be preceded by the words they stand for in the first instance of use

    • At first mention of a manufacturer, the town (and state if USA) and country should be provided

    • At the end of the article, give the name and complete mailing address, as well as the email address, to whom correspondence should be directed.


    Page proofs will be sent to the (one) corresponding author as designated when the manuscript was uploaded to Manuscript Central. It is the corresponding author's responsibility to share the page proofs with co-authors and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors. Changes in authorship in page proofs are NOT permitted under any circumstance.

    Reprints. Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    Publisher. The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740-2100; Fax: (914) 740-2101; Email: info@ liebertpub.com; Website: www.liebertpub.com

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy

    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 




The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Viral Immunology

    Viral Immunology

    The only journal reporting on all aspects of the rapidly growing field of viral immunology, with comprehensive coverage of immune responses to viral infections from basic mechanisms to clinical applications.

    Monoclonal Antibodies
    in Immunodiagnosis
    and Immunotherapy

    Monoclonal Antibodies
    in Immunodiagnosis
    and Immunotherapy

    The essential journal for scientists and clinicians in the fields of molecular immunology and immunopathology, and for all those applying molecular immunological methods for experimental and therapeutic purposes.

    AIDS Research and Human Retroviruses

    AIDS Research and Human Retroviruses

    The leading journal in the field for over 25 years, providing the latest developments and research advances in HIV/AIDS and other retroviruses leading to improvements in translational medicine for optimal treatment outcomes.

    Cancer Biotherapy and Radiopharmaceuticals

    Cancer Biotherapy and Radiopharmaceuticals

    The established journal with over 25 years of peer-reviewed papers on new and innovative investigations of methods to improve cancer therapy. The Journal focuses on advancements in radioimmunotherapy and radiopharmaceuticals.

Browse All Publications »